Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #3671: Lipidic nanoparticles in combined chemotherapy: In vivo inhibition of melanoma B16F10 growth

Iara Kretzer, Durvanei Maria, Valduga Claudete, Thais Contente and Raul Maranhão
Iara Kretzer
Faculty of Pharmaceutical Sciences of University of S%E3o Paulo, Sao Paulo, Brazil; Butantan Institute, S%E3o Paulo, Brazil; Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo and Bandeirante University, S%E3o Paulo, Brazil; Faculty of Medicine of University of S%E3o Paulo, S%E3o Paulo, Brazil; Faculty of Pharmaceutical Sciences and Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo, S%E3o Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Durvanei Maria
Faculty of Pharmaceutical Sciences of University of S%E3o Paulo, Sao Paulo, Brazil; Butantan Institute, S%E3o Paulo, Brazil; Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo and Bandeirante University, S%E3o Paulo, Brazil; Faculty of Medicine of University of S%E3o Paulo, S%E3o Paulo, Brazil; Faculty of Pharmaceutical Sciences and Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo, S%E3o Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valduga Claudete
Faculty of Pharmaceutical Sciences of University of S%E3o Paulo, Sao Paulo, Brazil; Butantan Institute, S%E3o Paulo, Brazil; Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo and Bandeirante University, S%E3o Paulo, Brazil; Faculty of Medicine of University of S%E3o Paulo, S%E3o Paulo, Brazil; Faculty of Pharmaceutical Sciences and Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo, S%E3o Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thais Contente
Faculty of Pharmaceutical Sciences of University of S%E3o Paulo, Sao Paulo, Brazil; Butantan Institute, S%E3o Paulo, Brazil; Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo and Bandeirante University, S%E3o Paulo, Brazil; Faculty of Medicine of University of S%E3o Paulo, S%E3o Paulo, Brazil; Faculty of Pharmaceutical Sciences and Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo, S%E3o Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raul Maranhão
Faculty of Pharmaceutical Sciences of University of S%E3o Paulo, Sao Paulo, Brazil; Butantan Institute, S%E3o Paulo, Brazil; Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo and Bandeirante University, S%E3o Paulo, Brazil; Faculty of Medicine of University of S%E3o Paulo, S%E3o Paulo, Brazil; Faculty of Pharmaceutical Sciences and Lipid Metabolism Laboratory of the Heart Institute (INCOR) of the Medical School Hospital of University of S%E3o Paulo, S%E3o Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Introduction and Objective: Lipidic nanoemulsions that resemble low-density lipoprotein (LDL) binds to LDL receptors and after injection into the bloodstream concentrates in neoplastic tissues wherein those receptors are upregulated. Thus the nanoemulsion can be used as vehicle to direct chemotherapeutic agents to malignant tumors. It was shown that the nanoemulsion increases the therapeutic index of carmustine, paclitaxel and etoposide in murine oncologic models. In patients with advanced cancer it pronouncedly decreases the toxicity of those drugs. This study aims to evaluate in melanoma bearing mice the effects of combined chemotherapy of paclitaxel and etoposide both associated with the nanoemulsion. Materials and Methods: Derivative forms of etoposide and paclitaxel were synthesized and associated to the nanoemulsion prepared by prolonged ultrassonication in aqueous medium and ultracentrifugation. B16F10 melanoma tumor-bearing mice were intraperitonially injected with paclitaxel oleate (9 \#956;mol/kg) and etoposide oleate (9 \#956;mol/kg) associated with the nanoemulsion at days 11th, 13th and 15th after the tumor cells inoculation. This group was compared to melanoma-bearing mice injected with equivalent doses of the single drugs associated with the nanoemulsion, combined therapy with the commercial formulations of paclitaxel and etoposide and a control group treated with saline solution. Tumor growth, presence of metastatic nodes, blood cell counts, and histological data from tumor samples from all treatment groups and controls were evaluated. Results: The tumor growth inhibition rate was over 85% in all treatment groups (p < 0,001) compared to controls. However, the group treated with the nanoemulsion drug combination presented tumors with the smallest cellular density, massive production of collagen fibers and reduction of newly formed vessels. This group also had the smaller percentage of animals bearing metastasis (30%) in comparison to the other treatments (p < 0,05). Blood cell counts showed that all treatments reduced characteristical hematopoietic effects of melanoma such as anemia and thrombocytosis (p < 0,001). Conclusion: Combined drug-targeting therapy of paclitaxel and etoposide derivatives associated to a lipidic nanoemulsion inhibited tumor growth with reduced hematological toxicity, and prevented tumor dissemination more effectively than the single therapy with the two drugs and the combination of commercial formulations of paclitaxel and etoposide.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3671.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #3671: Lipidic nanoparticles in combined chemotherapy: In vivo inhibition of melanoma B16F10 growth
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #3671: Lipidic nanoparticles in combined chemotherapy: In vivo inhibition of melanoma B16F10 growth
Iara Kretzer, Durvanei Maria, Valduga Claudete, Thais Contente and Raul Maranhão
Cancer Res May 1 2009 (69) (9 Supplement) 3671;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #3671: Lipidic nanoparticles in combined chemotherapy: In vivo inhibition of melanoma B16F10 growth
Iara Kretzer, Durvanei Maria, Valduga Claudete, Thais Contente and Raul Maranhão
Cancer Res May 1 2009 (69) (9 Supplement) 3671;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Drug Delivery Systems -- Poster Presentations - Proffered Abstracts

  • Abstract #3665: Improved therapeutic efficiency of doxorubicin by conjugation to Fe3O4@TiO2 nanoparticles
  • Abstract #3667: A novel folate receptor-targeted nanoparticle minimizes drug resistance in a human cancer model
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement